Back to catalogue
EKF

Ekf Diagnostics Holdings PLC

Health Care First-pass screen £115m
450/1000 Overall fit
AI beneficiary 35% 30
Operating leverage 25% 67
Valuation 25% 30
Downside protection 15% 66

First-pass take

9.3% EBITDA growth on 2.8% revenue growth and 51% gross margins demonstrate operating leverage; net cash £13.7m and zero debt provide downside protection. Diagnostics business has no AI exposure. No share price data available for valuation assessment.

Flags

no-ai-datano-valuation-datacustomer-concentrationgeopolitical-riskmicro-cap